A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: A randomized, double-blind clinical trial

Journal of Infectious Diseases

Volumn 207, Issue 6, 2013, Pages 957-965

  Durbin, Anna P ^a   Kirkpatrick, Beth D ^b   Pierce, Kristen K ^b   Elwood, Daniel ^a   Larsson, Catherine J ^b   Lindow, Janet C ^b   Tibery, Cecilia ^a   Sabundayo, Beulah P ^a   Shaffer, Donna ^a   Talaat, Kawsar R ^a   Hynes, Noreen A ^a,d   Wanionek, Kimberli ^a   Carmolli, Marya P ^b   Luke, Catherine J ^c   Murphy, Brian R ^c   Subbarao, Kanta ^c   Whitehead, Stephen S ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

clinical trial; dengue vaccine; live attenuated tetravalent

Indexed keywords

DENGUE VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; PLACEBO;

ADULT; AFRICAN AMERICAN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; MALE; MULTICENTER STUDY; MYALGIA; NEUTROPENIA; NORMAL HUMAN; ORBIT DISEASE; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RETROORBITAL PAIN; SIDE EFFECT; SINGLE DRUG DOSE; VIREMIA;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AMERICAN NATIVE CONTINENTAL ANCESTRY GROUP; ANTIBODIES, VIRAL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DOUBLE-BLIND METHOD; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXANTHEMA; FEMALE; HUMANS; MALE; OCEANIC ANCESTRY GROUP; VACCINES, ATTENUATED; VIREMIA; YOUNG ADULT;

EID: 84874264885     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis936     Document Type: Article

References (40)

1. Beatty ME, Stone A, Fitzsimons DW, et al. Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards. PLoS Negl Trop Dis 2010; 4:e890.
2. Halstead SB, Suaya JA, Shepard DS. The burden of dengue infection. Lancet 2007; 369:1410-1.
3. Gubler DJ, Meltzer M. Impact of dengue/dengue hemorrhagic fever on the developing world. Adv Virus Research 1999; 53:35-70.
4. Fox A, Le NM, Simmons CP, et al. Immunological and viral determinants of dengue severity in hospitalized adults in Ha Noi, Viet Nam. PLoS Negl Trop Dis 2011; 5:e967.
5. Simmons CP, Farrar JJ, Nguyen VV, Wills B. Dengue. N Engl J Med 2012; 366:1423-32.
6. Imrie A, Meeks J, Gurary A, et al. Antibody to dengue 1 detected more than 60 years after infection. Viral Immunol 2007; 20:672-5.
7. Sabin A. Research on dengue during World War II. Am J Trop Med Hyg 1952; 1:30-50.
8. Papaevangelou G, Halstead SB. Infections with two dengue viruses in Greece in the 20th century. Did dengue hemorrhagic fever occur in the 1928 epidemic? Am J Trop Med Hyg 1977; 80:46-51.
9. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, Morier L. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 1990; 42:179-84.
10. Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 1988; 38:172-80.
11. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2-9.
12. Gibbons RV, Kalanarooj S, Jarman RG, et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg 2007; 77:910-3.
13. Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 2011; 29:7242-50.
14. Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 2001; 65:405-13.
15. Durbin AP, McArthur J, Marron JA, et al. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin 2006; 2:167-73.
16. Durbin AP, McArthur JH, Marron JA, et al. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum Vaccin 2006; 2:255-60.
17. Durbin AP, Schmidt A, Elwood D, et al. Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic. J Infect Dis 2011; 203:327-34.
18. Durbin AP, Whitehead SS, McArthur J, et al. rDEN4 Delta 30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 2005; 191:710-8.
19. Durbin AP, Whitehead SS, Shaffer D, et al. A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial. PLoS Negl Trop Dis 2011; 5:e1267.
20. McArthur JH, Durbin AP, Marron JA, et al. Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am J Trop Med Hyg 2008; 79:678-84.
21. Edelman R, Wasserman SS, Bodison SA, et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003; 69:48-60.
22. Capeding RZ, Luna IA, Bomasang E, et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 2011; 29:3863-72.
23. Lang J. Recent progress on Sanofi Pasteur's dengue vaccine candidate. J Clin Virol 2009; 46(Suppl 2):S20-4.
24. Kouri GP, Guzman MG, Bravo JR, Triana C. Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic 1981. Bull World Health Organ 1989; 67:375-80.
25. Blanton RE, Silva LK, Morato VG, et al. Genetic ancestry and income are associated with dengue hemorrhagic fever in a highly admixed population. Eur J Hum Genet 2008; 16:762-5.
26. Halstead SB, Streit TG, Lafontant JG, et al. Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am J Trop Med Hyg 2001; 65:180-3.
27. Bravo JR, Guzman MG, Kouri GP. Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Trans R Soc Trop Med Hyg 1987; 81:816-20.
28. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010; 201:370-7.
29. Sun W, Cunningham D, Wasserman SS, et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccin 2009; 5:33-40.
30. Crum-Cianflone NF, Roediger M, Huppler Hullsiek K, et al. The-association of ethnicity with antibody responses to pneumococcal vaccination among adults with HIV infection. Vaccine 2010; 28:7583-8.
31. Granoff DM, Shackelford PG, Pandey JP, Boies EG. Antibody responses to Haemophilus influenzae type b polysaccharide vaccine in relation to Km(1) and G2m(23) immunoglobulin allotypes. J Infect Dis 1986; 154:257-64.
32. Montefiori DC, Metch B, McElrath MJ, Self S, Weinhold KJ, Corey L. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J Infect Dis 2004; 190:1962-9.
33. Guy B, Barban V, Mantel N, et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009; 80:302-11.
34. Anderson KB, Gibbons RV, Edelman R, et al. Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate. J Infect Dis 2011; 204:442-50.
35. Payne AM. Oral immunization against poliomyelitis. Bull World Health Organ 1960; 23:695-703.
36. Maldonado YA, Pena-Cruz V, de la Luz Sanchez M, et al. Host and viral factors affecting the decreased immunogenicity of Sabin type 3 vaccine after administration of trivalent oral polio vaccine to rural Mayan children. J Infect Dis 1997; 175:545-53.
37. Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan GH. Liveattenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 2011; 30:e9-17.
38. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380:1559-67.
39. Santangelo JD. DENVax: A live attenuated tetravalent dengue vaccine for dengue fever. In: World Vaccine Manufacturing Congress. Washington DC, 2012.
40. Mahoney RT, Francis DP, Frazatti-Gallina NM, et al. Cost of production of live attenuated dengue vaccines: A case study of the Instituto Butantan, Sao Paulo, Brazil. Vaccine 2012; 30: 4892-6.